AstraZeneca PLC (LON: 0A4J)

Market Cap	159.00B
Revenue (ttm)	38.20B
Net Income (ttm)	4.85B
Shares Out	n/a
EPS (ttm)	3.10
PE Ratio	32.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Aug 9, 2024

Volume	6,416
Open	64.56
Previous Close	65.30
Day's Range	64.33 - 64.73
52-Week Range	60.48 - 87.62
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 89,900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD